TRCT
MBVX

Tower Research Capital (TRC)’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-110
Closed -$1K – 4782
2016
Q3 		$1K Buy
+110
New +$1.66K ﹤0.01% 3469

Other funds holding MBVX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
DRD
Dennis R. Delaney $282M AUM 16.32% 1-Year Est. Return

Tower Research Capital (TRC)'s MBVX Position: Q4 2016 in Review

Tower Research Capital (TRC) sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q4 2016, closing a stake of 110 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in MBVX in Q3 2016 and held it in 1 quarter. The position peaked at $1K in Q3 2016. 7 funds tracked by Wall St. Rank hold MBVX as of Q4 2016.

  • Tower Research Capital (TRC) reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q4 2016 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 110 MABVAX THERAPEUTICS HLDGS INC shares in Q4 2016, an estimated $1K.
  • Tower Research Capital (TRC) first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q3 2016 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s MABVAX THERAPEUTICS HLDGS INC position peaked at $1K in Q3 2016.
  • 7 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q4 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2016, filed 3 Feb 2017.